

4(PRTS)

10/539627

JC17 Rec'd PCT/PTO 17 JUN 2005

PEPTIDES AND THEIR USE FOR THE TREATMENT OF HIV INFECTIONS

5 The present invention relates to peptides which exhibit inhibitory activity on the infection of human cells by human immunodeficiency virus (HIV).

Technical Background

10 In the last years, intensive research for therapeutics with activity against infection by HIV was performed. Several medicaments were developed and tested, which delay and suppress the outbreak of AIDS and lower the level of the HIV in blood. In the US the life-span of HIV-infected patients after the outbreak of AIDS was raised from 11 month in 1984 to 46 month in 1997.

15 In the search for therapeutics various strategies were applied, which lead to several classes of medicaments such as the protease-blockers inhibiting a protease, which the virus requires for replication, and medicaments inhibiting the viral reverse transcriptase, which is essential for the replication of retroviruses. A group of active agents developed only recently are fusion inhibitors, which shall prevent the entry of the virus into cells. It was also shown that the provision of interleukin-2 in combination with other active
20 agents could increase the strength of the immune response.

Entry inhibitors block the uptake of HIV viral particles into blood cells by blocking one of the molecular steps occurring during viral entry. An important step is binding of HIV to one of the major chemokine coreceptors CCR5 and CXCR4 (CC chemokine receptor 5 and CXCR chemokine receptor 4). These
25 coreceptors are located on the surface of blood cells and are required to bind to HIV envelope proteins before viral entry. Another step of viral interaction with cells required for fusion is the binding of the HIV envelope protein gp120 to cellular CD4 receptors. These steps are often referred to as attachment of the viral particle to cellular targets. The blocking of the binding of HIV to
30 chemokine coreceptors has been shown to suppress viral entry (Strizki-J.M., Proc. Natl. Acad Sci. USA, 2001, 98, 12718-12723). The same was reported by blocking the interaction of gp120 with CD4 receptors (Lin et al., Proc. Natl. Acad Sci. USA, 2003, 100, 11013-11018). The HIV protein gp41 has also been

recognised as a potential target for anti-HIV drug development (Gordon et al., AIDS Research and Human Retroviruses 11, 677-686, 1995). The first approved fusion inhibitor is enfuvirtide (T-20, Fuzeon, DP178) (WO 01/51673 A2; WO 96/40191; Cervia J.S et al., Clin. Infect. Dis, 2003, 37, 1102-1106; 5 Kilby J.M., Nature Medicine, 1998, 4, 1302-1307). This fusion inhibitor is identical to a part of the HIV envelope protein gp41 called HR-2 and inhibits HIV-cell fusion by binding to the HR-1 segment (HR = heptad repeat) of gp41 (Figure 4), thus preventing the binding of HR-2 to the HR-1 segment of gp41 which in turn prevents the formation of a six-helix bundle required for fusion 10 of the viral particle and the blood cell. T-20 has not been shown to bind to protein segments other than HR-1 of HIV gp41 or even other molecules of viral or eukaryotic origin. A further agent with biological activity against HIV was recently described in WO 01/34640. Disclosed is a peptide of 20 amino acids named VIRIP (virus inhibiting peptide), which was isolated from human 15 hemofiltrate and found to inhibit the infection of human cells by HIV.

Despite those efforts and different available medication, the problem remains unsolved that there is still no cure against AIDS, because the known therapeutics, though capable of significantly lowering the level of HIV in the body and of HIV-infected blood cells, do not remove the virus entirely. A 20 special drawback is, that the HIV is especially prone to mutations, which often result in the development of resistance against certain therapeutics. In general, the known therapeutics are only sufficiently effective if they are administered in combination with other therapeutics. Such combined therapies at present extend the lifespan of the average patient without providing a cure, 25 and are generally accompanied by severe side effects and frequently do not allow the patient to lead a "normal" life.


There is a great medical need to provide new therapeutics and improved therapeutics, which will lead to improved therapies, less side effects, and significant extension of the life expectancy of those infected by HIV, before or 30 after the outbreak of AIDS.

The present invention faces the problem to provide new therapeutics, which will overcome the problems as described above, and will allow an efficient therapy or will contribute to an efficient combination therapy.

Summary of the Invention

5 Surprisingly, the problem is solved by peptides provided by the present invention, which interact at least with the fusion peptide of HIV gp41. The fusion peptide is the very amino-terminal part of gp41 consisting of about 30 amino acid residues. In a current model, the hydrophobic fusion peptide of gp41 serves as an anchor connecting the viral particle with the cellular host
10 membrane (Dimitrov A.S. et al., Biochemistry, 2003, 42, 14150-14158; Mobley et al., Biochim. Biophys. Acta, 1999, 1418, 1-18), and the peptides of the present invention interfere with the HIV cell fusion process, and thus prevent viral entry.

The peptides of the present invention are those with a biological activity
15 against HIV infection, having amino acid sequence



wherein

X₁ is a lysine, alanine, or aspartic acid;

X₂ is a cysteine, methionine or isoleucine;

20 X₃ is a serine, cysteine, lysine or glycine;

X₄ is an isoleucine, alanine, phenylalanine or cysteine;

X₅ is a proline, D-proline or a substituted L-or D-proline;

X₆ is a cysteine or glutamic acid;

25 X₇ is an amino acid with a hydrophobic or an aromatic side chain or cysteine;

X₈ is an amino acid with a hydrophobic or an aromatic side chain or cysteine;

X₉ is an amino acid with an aromatic side chain;

X₁₀ is a glycine, alanine or asparagine;

30 X₁₁ is a proline, aspartic acid, octahydroindolyl-2-carboxylic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;

X₁₂ is a phenylalanine, alanine, glycine, glutamic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;

X_{13} is an amino acid with a hydrophobic or an aromatic side chain;

X_{14} is an amino acid with a hydrophobic or an aromatic side chain;

X_{15} is a phenylalanine or deletion;

Z_1 is NH_2 or a sequence of 1 to 10 amino acid residues;

5 Z_2 is COOH or a sequence of 1 to 10 amino acid residues;

and peptides which are fragments and/or covalently linked oligomers and/or derivatives, especially amidated, alkylated, acylated, sulfated, pegylated, phosphorylated and/or glycosylated derivatives, and mutants thereof,

10 with the proviso that

(a) if X_{12} is alanine, glycine, glutamic acid, or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid then X_{13} , X_{14} and X_{15} are phenylalanine, valine and phenylalanine respectively; and/or

(b) if X_{12} is phenylalanine, then X_{13} , X_{14} and X_{15} are valine, 15 phenylalanine and a deletion, respectively; and

(c) that there are at maximum two cysteine residues in a peptide.

In a preferred embodiment of the above peptide with the generic formula

$Z_1\text{-LE-X}_1\text{-IP-X}_2\text{-X}_3\text{-X}_4\text{-P-X}_5\text{-X}_6\text{-X}_7\text{-X}_8\text{-X}_9\text{-X}_{10}\text{-K-X}_{11}\text{-X}_{12}\text{-X}_{13}\text{-X}_{14}\text{-X}_{15}\text{-Z}_2$,

X_7 is phenylalanine, cysteine, valine, isoleucine, leucine, 3,3-diphenylalanine, 20 1- naphthylalanine, or p-fluorophenylalanine; X_8 is a phenylalanine, leucine, alanine, tryptophan, glycine, cysteine, D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid or L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; X_9 is a phenylalanine or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; and Z_1 is preferably NH_2 or a sequence of 1 to 3 amino acid residues and Z_2 is 25 preferably COOH or a sequence of 1 to 3 amino acid residues. The biological activity against HIV infection of the above peptides, as measured as IC_{50} , is equal of or below of 6500 nM.

A further embodiment are peptides according to the invention with a biological 30 activity against infection by HIV, having the amino acid sequence

$Z_1\text{-LE-X}_1\text{-IP-X}_1\text{-X}_3\text{-X}_4\text{-P-X}_5\text{-X}_6\text{-X}_7\text{-X}_8\text{-X}_9\text{-X}_{10}\text{-K-X}_{11}\text{-FVF-Z}_2$,

wherein

X₁ is a lysine, alanine or aspartic acid;

X₂ is a cysteine, methionine or isoleucine;

X₃ is a serine, cysteine or glycine;

X₄ is an isoleucine or cysteine;

5 X₅ is a proline, D-proline or any substituted L- or D-proline;

X₆ is a cysteine or glutamic acid;

X₇ is a phenylalanine, cysteine, valine, isoleucine or 3,3-diphenyl-
alanine;

10 X₈ is a phenylalanine, leucine, alanine, glycine, cysteine, D-1,2,3,4-
tetrahydroisoquinoline-3-carboxylic acid or L-1,2,3,4-tetrahydro-
isoquinoline-3-carboxylic acid;

X₉ is an amino acid with an aromatic side chain;

X₁₀ is a glycine or asparagine;

X₁₁ is a proline or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic;

15 Z₁ is NH₂ or a sequence of 1 to 10 amino acid residues;

Z₂ is COOH or a sequence of 1 to 10 amino acid residues;

and peptides which are fragments and/or covalently linked oligomers and/or
derivatives, especially amidated, alkylated, acylated, sulfated, pegylated,
phosphorylated and/or glycosylated derivatives, and mutants thereof,


20 with the proviso that

(a) if two cysteine residues are present, said residues are separated by
four other amino acid residues; and

(b) if L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, D-1,2,3,4-
tetrahydroisoquinoline-3-carboxylic acid and/or 3,3-diphenyl-
25 alanine are present, no cysteine residue is present.

In a preferred embodiment of the above peptide with the generic formula Z₁-
LE-X₁-IP-X₁-X₃-X₄-P-X₅-X₆-X₇-X₈-X₉-X₁₀-K-X₁₁-FVF-Z₂, X₉ is a phenylalanine or
D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, Z₁ is preferably NH₂ or a
sequence of 1 to 3 amino acid residues and Z₂ is preferably COOH or a
30 sequence of 1 to 3 amino acid residues. The biological activity against HIV
infection of the above peptide, as measured as IC₅₀, is equal of or below of
2000 nM.

An even further embodiment are peptides according the invention with a biological activity against infection by HIV, having the amino acid sequence




wherein

- 5 X₁ is a lysine, alanine or aspartic acid;
 X₂ is a cysteine, methionine or isoleucine;
 X₃ is a serine or glycine;
 X₅ is a L-proline, D-proline or any substituted L- or D-proline
 X₆ is a cysteine or glutamic acid;
10 X₇ is a phenylalanine or valine;
 X₈ is a phenylalanine, leucine, alanine or L-1,2,3,4-tetrahydro-
 isoquinoline-3-carboxylic acid;
 X₁₀ is a glycine or asparagine;
 Z₁ is NH₂ or a sequence of 1 to 10 amino acid residues;
15 Z₂ is COOH or a sequence of 1 to 10 amino acid residues;

and peptides which are fragments and/or covalently linked oligomers and/or derivatives, especially amidated, alkylated, acylated, sulfated, pegylated, phosphorylated and/or glycosylated derivatives, and mutants thereof.

- In a preferred embodiment of the peptide with the generic formula Z₁-LE-X₂-
20 IP-X₂-X₃-IP-X₅-X₆-X₇-X₈-F-X₁₀-KPFVF-Z₂, Z₁ is preferably NH₂ or a sequence of 1
to 3 amino acid residues and Z₂ is preferably COOH or a sequence of 1 to 3
amino acid residues. The biological activity against HIV infection of the
peptide, as measured as IC₅₀, is equal of or below of 800 nM.

- 25 An even further embodiment are peptides of the invention with biological
activity against infection by HIV, having the amino acid sequence



wherein

- X₂ and X₆ are cysteines, or X₂ is methionine and X₆ is glutamic acid
30 X₅ is a D-proline or L-proline;
 X₈ is an amino acid with a hydrophobic or an aromatic side chain or
 lysine;

Z_1 is NH_2 or a sequence of 1 to 10 amino acid residues;

Z_2 is COOH or a sequence of 1 to 10 amino acid residues;

and peptides which are fragments and/or covalently linked oligomers and/or derivatives, especially amidated, alkylated, acylated, sulfated, pegylated, phosphorylated and/or glycosylated derivatives, and mutants thereof,
5 with the proviso that at least one of the following is true:

X_2 is proline or

X_5 is not leucine or

X_6 and X_8 are cysteine.

10 In a preferred embodiment of the peptide with the generic formula $Z_1\text{-LEAIP-}X_2\text{-SIP-}X_5\text{-}X_6\text{-V-}X_8\text{-FNKPFVF-}Z_2$, Z_1 is preferably NH_2 or a sequence of 1 to 3 amino acid residues and Z_2 is preferably COOH or a sequence of 1 to 3 amino acid residues.

15 Also an embodiment of the peptides of the present invention are those, wherein the cysteine residues at positions 6 and 11, 6 and 12, 7 and 12, or 8 and 13 are connected by an intramolecular disulfide bond. The peptides with cysteine residues at these positions may occur with an intramolecular bridge between these residues, or, under reductive conditions as linear molecules. A
20 further embodiment are peptides with a single cysteine residue, wherein said cysteine residue is connected by an inter-molecular disulfide bond to another peptide molecule with a single cysteine residue, forming a homo-dimer. Also embodiments are those peptides, wherein the leucine residue at amino acid position 1 and the glutamic acid at amino acid position 2 are covalently linked
25 by an N-alkylated amide bond or by an ester bond or by a reduced peptide bond or by a retro-inverso peptide bond or by an N-alkylated retro-inverso peptide bond. A further embodiment are peptides which interact with the HIV fusion peptide of gp41. The peptides of the present invention are characterised by an IC_{50} of equal or below 6500 nM, preferably an IC_{50} of equal or below
30 2000 nM and most preferably an IC_{50} of equal or below 800 nM, such as VIR-344 (SEQ ID NO. 49) with an IC_{50} of 348 nM, VIR-345 (SEQ ID NO. 50) with an IC_{50} of 298 nM, VIR-353 (SEQ ID NO. 56) with an IC_{50} of 225 nM, VIR-357 (SEQ ID NO. 60) with an IC_{50} of 497 nM, VIR-358 (SEQ ID NO. 61) with an

IC₅₀ of 706 nM, VIR-449 (SEQ ID NO 73) with an IC₅₀ of 274 nM, VIR-455 (SEQ ID NO 76) with an IC₅₀ of 134 nM, VIR-484 (SEQ ID NO 79) with an IC₅₀ of 100 nM, VIR-512 (SEQ ID NO. 83) with an IC₅₀ of 138 nM, VIR-576 (SEQ ID NO: 86) with an IC₅₀ of 107 nM and VIR-580 (SEQ ID NO. 87) with an IC₅₀ of 150 nM.

Also the nucleic acids coding for these peptides are embodiments of the present invention. Further embodiments are antibodies binding specifically to these peptides. A further embodiment is a medicament containing anyone of these peptides, nucleic acids coding for these peptides, or specific antibodies directed against these peptides. In one embodiment the medicament is in galenic formulations for oral, intravenous, intramuscular, intracutaneous, subcutaneous, intrathecal administration, and as an aerosol for transpulmonary administration. A further embodiment is said medicament comprising at least one further therapeutic agent. Also an embodiment is the medicament, wherein the said at least one further therapeutic agent is a viral protease inhibitor, a reverse transcriptase inhibitor, a fusion inhibitor, a cytokine, a cytokine inhibitor, a glycosylation inhibitor or a viral mRNA inhibitor, etc. Use of these peptides for the manufacturing of a medicament for the treatment of HIV infections is a further embodiment. Also an embodiment is an assay for determining molecules capable of interacting with the fusion peptide of HIV, comprising anyone of the above peptides of the invention. Use of these peptides in said assay is also an embodiment. A further embodiment is a diagnostic agent containing these peptides, nucleic acids or antibodies. One more embodiment is use of the diagnostic agent for assay systems for testing isolated plasma, tissue, urine and cerebrospinal fluid levels for HIV infection. Further specific embodiments of the present invention are the peptides according to claim 8.

Brief Description of the Drawings

Figure 1: C18 HPLC trace of purified VIR-199 (sequence: LEAIPMSIPpEFLFNKPFVF) (SEQ ID NO. 18). Conditions: Vydac C18 (4.6 × 250 mm, 300 Å, 5 µm, flow rate: 0.8 ml/min, gradient: 10-70 volume % B in 30

min, buffer A: 0.07 volume % TFA, buffer B: 0.05 volume % TFA, 80 volume % acetonitrile).

5 Figure 2: Electrospray-ionization mass spectrum (ESI-MS) of purified VIR-199 (sequence: LEAIPMSIPpEFLFNKPFVF) (SEQ ID NO. 18). The mass spectrum was recorded using a Sciex API 100 mass spectrometer. The molecular ions for $[M+2H]^{2+}$ (m/z 1169.0) and $[M+3H]^{3+}$ (m/z 780.0) are indicated.

10 Figure 3: Dose dependent inhibition of fusion peptide hemolysis by various VIRIP peptides. The peptides (VIRIP (SEQ ID NO. 1), VIR-164 (SEQ ID NO. 6), VIR-165 (SEQ ID NO. 7), VIR-175 (SEQ ID NO. 10), VIR-269 (SEQ ID NO. 35) at 1000 μ M, 100 μ M and 10 μ M were preincubated with 100 μ M fusion peptide and the hemoglobin release in human erythrocytes was measured. The Y-axis reflects the inhibition of the fusion peptide-induced hemolysis
15 depending of the concentration of peptides. The extent of inhibition of hemolysis is thus a measure for the binding of peptides to the fusion peptide. Peptides that exhibit lower IC_{50} values than VIRIP inhibit more effectively infection of cells compared to VIRIP.

20 Figure 4: Schematic drawing of gp41. The three domains, the fusion peptide (FP) domain, the HR-1 and HR-2 domains are indicated. The fusion peptide is located at the N-terminus of gp41.

25 Detailed Description of the Invention

The peptides of the present invention are related to the hemofiltrate-derived peptide VIRIP (SEQ ID No. 1) as disclosed and described in WO 01/34640, which has biological activity in preventing infection by HIV. They all differ from
30 VIRIP at least in amino acid position 13, where VIRIP contains a lysine residue, while the peptides of the present invention do not contain a lysine residue at amino acid position 13. In addition to that, the peptides of the present invention have further amino acid changes throughout their 21 amino

acids in comparison to VIRIP. The peptides of the present invention all possess significantly higher anti-HIV activity (measured as IC_{50} against two HIV-1 strains) than VIRIP. The increase in anti-HIV activity is at least 4-fold (VIR-184, SEQ ID NO. 12), and the very active peptides of the present invention
5 are up to 161-fold (e.g. VIR-280, SEQ ID NO. 39) more active against HIV than VIRIP.

The peptides of the invention are based on an amino acid sequence of 21 amino acids, with possible extensions of 1 to 10 amino acids at both ends according to Z_1 and Z_2 , whereby an extension of 3 amino acids is preferred.
10 The amino acid numbering used herein always corresponds to the amino acids 1 to 21 of the basic sequence irrespective of a possible N-terminal extension due to a residue Z_1 , such that amino acid position 1 corresponds to leucine and amino acid position 21 to phenylalanine or a deletion. The common amino acid one and three letter codes are used. If not indicated otherwise, the L-
15 enantiomers of amino acids were used. The small letter "p" stands for D-proline. Other D-enantiomers are indicated by a "D-" prefix. "Tic" stands for tetrahydroisiquinoline carboxylic acid. "Oic" stands for octahydroindole carboxylic acid.

The term "hydrophobic amino acid" as used herein is readily understood by
20 the skilled person. In particular, it refers to any of the amino acids glycine, alanine, valine, leucine, isoleucine, methionine, proline, phenylalanine, tyrosine, tryptophan, and non-endogenous hydrophobic amino acids.

The term "aromatic amino acid" as used herein is readily understood by the skilled person. In particular it refers to any of the amino acids phenylalanine,
25 tyrosine, tryptophan, histidine, and non-endogenous aromatic amino acids, such as 1-naphthylalanine, 3,3-diphenylalanine, p-fluorophenylalanine, or D-1,2,3,4-tetrahydroisiquinoline-3-carboxylic acid or L-1,2,3,4-tetrahydroisiquinoline-3-carboxylic acid, etc.

The term "mutants" is readily understood by the skilled person. In particular,
30 it refers to sequence variants, in which one or more of the amino acids as disclosed are changed, i.e. one or more amino acids are substituted by another one. Mutants of the invention preferably vary from a peptide of claim

1 by one, two, three or four amino acids. In a preferred embodiment, the mutations are conservative, such that the properties of the side chain of the changed amino acids do not vary substantially from the original amino acid. Mutants also include sequence variants, wherein one or more amino acids are
5 deleted from the sequence or inserted into the sequence.

The term "fragments" is readily understood by the skilled person. In particular it refers to sequence variants in which the sequence is truncated at the N- or C-terminus. In preferred embodiments, the peptides lack up to 2, 4 or 6 amino acids at the N- and/or C- terminus.

10 The term "covalently linked oligomers" is readily understood by the skilled person. In particular it refers to multiple peptide chains covalently linked to each other. The peptide chains can have the identical or a different amino acid sequence. The covalent bond can be a direct bond between the respective peptide chains such as a disulfide bond, thioether bond, ether bond, amide
15 bond. The peptide chains can also be covalently linked by a spacer of any chemical nature (Houben-Weyl, Methods of organic chemistry, Synthesis of peptides and peptidomimetics, Georg Thieme Verlag, Stuttgart 2002).

The term "derivative" is readily understood by the skilled person. In particular it refers to a chemically modified peptide. This modification could be a single
20 amino acid substitution, multiple substitutions or different chemical modifications of the peptide at the N- and C-terminus, the side chains of the peptide, the C α - and N α -atoms of the peptide backbone, and the atoms forming the peptide bonds of the backbone.

The term "amidated" is readily understood by the skilled person. In particular
25 it refers to a modification of a peptide in which the C-terminal carboxyl group is replaced by an CONR₂-group where R is a hydrogen atom or any functional group that can replace at least one of the hydrogen atoms.

The term "acylated" is readily understood by the skilled person. In particular it refers to peptides that contain a covalently linked carboxylic acid residue other
30 than an amino acid at amino groups at the N-terminus and/or at side chains of amino groups.

The term "alkylated" is readily understood by the skilled person. In particular

it refers to peptides which are modified with an alkyl group of various length and structure at the N-terminal amino group, at any backbone atom and/or at any functional group of a side chain.

5 The term "sulfated" is readily understood by the skilled person. In particular it refers to peptides carrying a sulfate moiety at the hydroxyl group of a tyrosine or substituted tyrosine derivative residue.

The term "pegylated" is readily understood by the skilled person. In particular it refers to peptides which contain covalently linked a polyethyleneglycol (PEG) moiety consisting of at least two repeating units $-\text{CH}_2-\text{CH}_2-\text{O}-$ typical of
10 polyethyleneglycol. Preferred is a so-called mini-PEG group. Pegyl groups may have a molecular weight of up to 20 KDa and can be bound to different functional groups in a peptide sequence directly or via a spacer group at the N- and/or C-terminus and/or side chain functional groups. The spacer group is selected from the group of bifunctional hydrocarbon chains characterised by a
15 backbone of two, three, four, five, six, seven, eight or nine carbon atoms, and two functional groups, such as two amino groups, two carboxyl groups or one amino group and one carboxyl group. One or more pegyl groups can be contained at different sites of a peptide.

The term "phosphorylated" is readily understood by the skilled person. In
20 particular it refers to peptides where the hydroxy groups of the side chains of threonine, serine, hydroproline, hydroxylysine, tyrosine, and/or any other non-natural hydroxy amino acid is esterified with a phosphate group.

The term "glycosylated" is readily understood by the skilled person. In particular it refers to peptides that contain a monomeric and/or oligomeric
25 carbohydrate moiety which is linked via the glycosilic or an alcoholic hydroxy group to the side chains of serine, threonine, tyrosine, asparagine, and/or non-natural amino acids.

The term "cyclic" is readily understood by the skilled person. In particular it refers to peptides that contain a cyclic structural motif. The cyclization can be
30 achieved by backbone cyclization or by linking a side chain of an amino acid to a side chain of a different amino acid present in the same molecule. In a preferred embodiment of the invention, two cysteine residues of a peptide or

one carboxylic acid side chain and one amino group-containing side chain form a cyclic motif via a disulfide bond or an amide bond. The peptides VIR-161 (SEQ ID NO. 3), VIR-162 (SEQ ID NO. 4), VIR-163 (SEQ ID NO. 5), VIR-164 (SEQ ID NO. 6), VIR-165 (SEQ ID NO. 7), VIR-166 (SEQ ID NO. 8), VIR-272 (SEQ ID NO. 36), VIR-273 (SEQ ID NO. 37), VIR-274 (SEQ ID NO. 38), VIR-280 (SEQ ID NO. 39), VIR-344 (SEQ ID NO. 49), VIR-345 (SEQ ID NO. 50), VIR-346 (SEQ ID NO. 51), VIR-348 (SEQ ID NO. 52), VIR-350 (SEQ ID NO. 53), VIR-351 (SEQ ID NO. 54), VIR-352 (SEQ ID NO. 55), VIR-353 (SEQ ID NO. 56), VIR-354 (SEQ ID NO. 57), VIR-355 (SEQ ID NO. 58), VIR-356 (SEQ ID NO. 59), VIR-357 (SEQ ID NO. 60), VIR-358 (SEQ ID NO. 61), VIR-568 (SEQ ID NO. 84), VIR-570 (SEQ ID NO. 85), VIR-576 (SEQ ID NO. 86) all possess two cysteine residues and may adapt a cyclic form. These peptides may also occur as linear molecules. Preferred embodiments are the cyclic form of these peptides since they are characterised by a higher structural and biological stability.

Surprisingly, it was found that by specifically varying the amino acid sequence of VIRIP (SEQ ID NO. 1), peptides with a significantly increased activity against HIV were obtained. The most significant increase in activity is observed, when the L-proline at position 10 is substituted by a D-proline, and/or two cysteines are introduced at amino acid positions 6 and 11, and/or when the positively charged lysine at position 13 is exchanged against an amino acid with a hydrophobic or aromatic side chain. It is believed that the activity when compared to wild-type VIRIP (SEQ ID NO. 1) is increased due to a change in structure. Cysteine bridges are known to alter the structure and to reduce the flexibility of a peptide significantly, as well as the introduction of a D-proline, which causes a change in secondary structural elements of a peptide and thus a changed orientation of different parts of the peptide to each other. Furthermore, the exchange of a lysine against an uncharged hydrophobic or aromatic amino acid will alter the structure, because a possible interaction of the positively charged lysine side chain with the negatively charged amino acids at positions 2 and 11 of the same molecule, or with a negatively charged portion of a receptor molecule is changed. A significant

increase in the anti-HIV activity is further observed when the alanine residue at position 3 is exchanged to a positively or negatively charge residue by substitution with lysine or aspartic acid residues. The introduction of a charged residue at position 3 can enhance the binding strength to a corresponding part of a receptor molecule by increased electrostatic or dipolar forces. The exchange of the amino acid residues at positions 7 or/and 15 against a small amino acid residue, in particular glycine, has also been found to increase the anti-HIV activity. Glycine residues are the least sterically hindering residues and allow an optimal internal structural arrangement of a peptide when binding to a receptor molecule or when forming aggregates with themselves required for binding with a receptor molecule. The described substitutions may be combined in peptides of the invention. Furthermore, the antiviral activity is increased when peptides of the invention are homooligomerized, in particular homodimerized. A dimerization of peptides of the invention can be achieved chemically by covalent linking of two identical peptide chains. The covalent link can be a direct bond between side chain functional groups such as the thiol group of cysteine residues, or a bond involving a spacer between the peptide chains as is present when two identical chains of a peptide of the invention are bound to the two amino groups of a lysine residue. The latter is often referred to as the smallest form of a lysine-core dendrimer (Sadler K., J. Biotechnology, 2002, 90, 195-229). Oligomers, in particular dimers of peptides of the invention, can induce a structurally and/or biologically more stable form of the molecules. In addition, they can increase the local concentration of the antivirally active peptide at the site of action. They can thus provide forms of the peptides of the invention which interact more favourable with a receptor molecule.

Peptides according to the invention can be easily chemically synthesised or produced by recombinant expression. Due to the small size, i.e. the low number of amino acid the peptides of the invention are composed of, the entire peptide synthesis technologies can be utilised to chemically synthesise such substances. In comparison to the synthesis of the HIV fusion inhibitor T-20, which requires the synthesis of three individual fragments, and

subsequently the joining of the three fragments to give rise to the final product T-20, the peptides of the present invention, can be synthesised at large scale by stepwise solid phase methods or by solution phase chemistry. Thus the manufacturing process of the peptides of the present invention is straightforward and therefore the costs of the goods comprising the peptides of the present invention are lower. A further advantage of the peptides of the present invention is their solubility and stability over a broad range of pH (pH 2 - 8.5) in solvents of different ionic strength.

The chemical synthesis can be carried out on a solid support using solid-phase technologies or in solution phase, both being standard methods known to the skilled person. Peptides according to the invention can also be synthesized by the ligation of two or more side chain-protected or side chain-unprotected fragments, standard methods known to the skilled person (Tam J.P., Biopolymers, 2001, 60, 194-205). The solid-phase synthesis of peptides according to the invention or its fragments can be carried out using the Fmoc/tBu- or Boc/Bzl-protection pattern of amino acids. Other protective groups that are not in the standard Fmoc-protection scheme can be used. Purification of synthetic peptides is achieved by chromatographic methods such as reverse-phase, ion exchange or size-exclusion. The chemical methods for the chemical synthesis of the peptides of the invention mentioned here are surveyed in several review publications (examples: Chan W.C. et al. (editors), Fmoc solid phase peptide synthesis: A practical approach, Oxford University Press, Oxford, 2000; Seewald N. et al., Peptides: biology and chemistry, Wiley-VCH, Weinheim, 2002; Goodman M., Houben-Weyl, Methods of organic chemistry, Synthesis of peptides and peptidomimetics, Georg Thieme Verlag, Stuttgart 2002).

The introduction of a disulfide bond into peptides of the invention may be achieved by applying oxidative chemical methods with peptides containing two cysteine residues known to the skilled person (Pennington et al. (editors), Peptide synthesis protocols, Humana Press, Totowa 1994; Chan W.C. et al. (editors), Fmoc solid phase peptide synthesis: A practical approach, Oxford University Press, Oxford, 2000). Disulfides of peptides of the invention may be

generated from reduced precursor peptides containing one or two unprotected cysteine residues obtained from solid-phase or solution synthesis by oxidative treatment. As oxidizing agents oxygen, dimethylsulfoxide, iron(III) salts, iodine, or others may be used. Disulfides of peptides of the invention may alternatively be introduced into the peptides from precursors containing protective groups at the corresponding cysteine residues. As protective groups acetamidomethyl, tert-butyl, S-tert-butyl or others may be used. Cleavage of protective groups and intra-chain disulfide bond formation may be carried out using agents such as iodine, phosphines, or others.

Cyclic peptides other than those with a disulfide bond can be obtained via backbone cyclization of the peptide or via a chemical bond between at least one reactive side chain group such as amino, carboxy, hydroxy or thio and any other reactive group present in the same molecule, as known to the skilled person (Li et al., Curr. Top. Med. Chem., 2002, 2, 325-341; Tam J.P., Biopolymers, 2001, 60, 194-205; Goodman M., Houben-Weyl, Methods of organic chemistry, Synthesis of peptides and peptidomimetics, Georg Thieme Verlag, Stuttgart 2002).

Covalently linked oligomers of peptides are obtained by linking two peptide chains via different types of chemical bonds. Disulfide-linked oligomers are synthesized by coupling the two peptide chains either via activated cysteines or without any preactivation of the cysteines (Sacca B. et al., J. Pept. Sci., 2002, 8, 192-204; Seewald N. et al., Peptides: biology and chemistry, Wiley-VCH, Weinheim, 2002). Thioether bonds and ether bonds and peptide bonds between two peptide chains can be introduced according to different methods known to the skilled person and described in the literature (Seewald N. et al., Peptides: biology and chemistry, Wiley-VCH, Weinheim, 2002). Lysine-core dendrimers can be synthesized by coupling Fmoc-Lys(Fmoc)-OH to a solid support. After deprotection of the amino acid solid phase peptide synthesis leads to the oligomeric peptides (Seewald N. et al., Peptides: biology and chemistry, Wiley-VCH, Weinheim, 2002; Chan W.C. (editors) Fmoc solid phase peptide synthesis: A practical approach, Oxford University Press, Oxford 2000). Lysine can be replaced by any other amino acid containing two amino groups.

Amidated peptides are obtained by solid phase peptide synthesis using resins carrying an amide linker on which the peptide chain is assembled. Acid cleavage of correspondingly synthesized peptides results in peptide amides. In solution phase synthesis amidated peptides are obtained when the C-terminal amino acid is used as a building block which has a preformed carboxamide at the C-terminus. (Chan W.C. (editors) *Fmoc solid phase peptide synthesis: A practical approach*, Oxford University Press, Oxford 2000).

Acylated peptides are obtained by the skilled person through converting a peptide with free amino or hydroxy groups using activated acylation reagents derived from carboxylic acids such as acyl halogenides or carboxylic anhydride or other reactive carbonyl compounds to a corresponding acylated peptide. As an alternative, acylation can be achieved using free carboxylic acids which are activated in situ by phosphonium- or uronium-type compounds (Greene T.W., *Protective groups in organic chemistry*, John Wiley & Sons, New York, 1991; Kocienski P., *Protecting groups*, Thieme-Verlag, Stuttgart 1994).

Alkylated peptides may be obtained by incorporating prealkylated amino acid building blocks when carrying out peptide synthesis on the solid support or in solution. Such amino acids are coupled onto the peptide chains using standard activation protocols known to the skilled person (Chan W.C. (editors) *Fmoc solid phase peptide synthesis: A practical approach*, Oxford University Press, Oxford 2000). Alkylation may also be achieved after assembly of a peptide chain by using appropriate alkylation methods known to the skilled person (Greene T.W., *Protective groups in organic chemistry*, John Wiley & Sons, New York, 1991; Kocienski P., *Protecting groups*, Thieme-Verlag, Stuttgart 1994). Such methods may be applied to reactive groups such as amino, hydroxy, thio and peptide bonds of the peptide backbone in a partially protected peptide.

Sulfated peptides are obtained by using presulfated building blocks of tyrosine or tyrosine derivatives in solid phase or solution peptide synthesis. O-sulfates remain attached to the hydroxy group during peptide cleavage from the resin when highly acid-labile resins such as 2-chlorotrityl resin are used for synthesis (Seewald N. et al., *Peptides: biology and chemistry*, Wiley-VCH,

Weinheim, 2002).

Pegylated peptides contain pegyl residues bound to functional groups of a peptide. Pegyl residues are characterized as hydrophilic linear or branched polymeric chains with a repeating unit $-\text{CH}_2-\text{CH}_2\text{O}-$. Pegyl residues are introduced into a peptide after assembly of the peptide chain using suitable functionally modified and reactive pegyl-containing substances. Various activated pegyl groups can be attached by the skilled person to peptides by different activation methods to different side chains or terminal functional groups of a peptide such as amino, carboxyl, hydroxy and thio (Veronese F.M. et al., *Bioconjug. Chem.*, 2001, 12, 62-70; Veronese F.M., *Biomaterials*, 2001, 22, 405-417).

Phosphorylated peptides can be synthesized by solid phase or solution phase peptide synthesis. Synthesis of phosphorylated peptides is usually achieved by the skilled person utilizing phosphorylated hydroxy amino acid building blocks and/or by post-chain assembly phosphorylation of protected peptides with one or more free hydroxy functional groups (Murray J.S., *Biopolymers*, 2001, 60, 3-31; Chan W.C. et al. (editors), *Fmoc solid phase peptide synthesis: A practical approach*, Oxford University Press, Oxford, 2000; Seewald N. et al., *Peptides: biology and chemistry*, Wiley-VCH, Weinheim, 2002).

Glycosylated peptides can be obtained by the skilled person using glycosylated amino acid building blocks which can be incorporated into solid phase or solution phase synthesis of peptides or by the global post-chain assembly glycosylation approach (Davis B.G., *Chem. Rev.*, 2002, 102, 579-602; Chan W.C. et al. (editors), *Fmoc solid phase peptide synthesis: A practical approach*, Oxford University Press, Oxford, 2000; Seewald N. et al., *Peptides: biology and chemistry*, Wiley-VCH, Weinheim, 2002).

The invention also relates to nucleic acids coding for peptides of the invention. Preferred nucleic acids are DNA and RNA, especially cDNA and mRNA.

Subject of the invention are also antibodies specifically binding to peptides of the invention. The term "specifically" is readily understood by the skilled person. In particular, it means that the antibodies do not bind or do essentially not bind related peptides like VIRIP which are not peptides of the invention. A

person skilled in the art obtains antibodies against peptides of the invention by routine methods, and will select specific antibodies of the invention by known screening methods.

The invention relates to peptides which specifically interact with and bind to the N-terminal region of the envelope protein gp41 of HIV. The term "interact with" and "bind to" is readily understood by the skilled person. By such binding and interaction, peptides of the invention block infection of host cells by HIV particles. The present invention also relates to peptides which bind to synthetic peptides corresponding to the fusion peptide of gp41 of HIV. A person skilled in the art detects binding and interaction of peptides of the invention to the synthetic fusion peptide of gp41 of HIV by applying quantitative structure/activity relationship (QSAR) assays. These assays comprise but are not limited to the detection of the suppression of the hemolytic effect of the synthetic fusion peptide (Mobley P.W. et al., *Biochim. Biophys. Acta*, 1992, 1139, 251-256; Gordon L., *Biochim. Biophys. Acta*, 1992, 1139, 257-274), microcalorimetry (Gohlke H. et al., *Angew. Chem. Int. Ed. Engl.*, 2002, 41, 2644-2676), or NMR-spectroscopical techniques which can be chemical shift titration experiments or saturation transfer difference spectroscopy (Meyer et al., *Ernst Schering Res. Found. Workshop*, 2004, 44, 149-167).

The invention also relates to a medicament containing the peptides, nucleic acids or antibodies of the invention. The medicament is preferably provided in galenic formulations for oral, intravenous, intramuscular, intracutaneous, subcutaneous, intrathecal administration, or as an aerosol for transpulmonary administration.

In a preferred embodiment, the medicament comprises at least one further therapeutic agent. Said at least one further therapeutic agent can be a viral protease inhibitor, a reverse transcriptase inhibitor, a fusion inhibitor, a cytokine, a cytokine inhibitor, a glycosylation inhibitor or a viral mRNA inhibitor, etc. Preferably, such inhibitors are directed against HIV. Such combined therapeutics are highly relevant in the treatment of AIDS. The peptides, nucleic acids and antibodies of the invention are preferably used in manufacturing of a medicament for the treatment of HIV infections. This

comprises all known strains of the retrovirus HIV (human immunodeficiency virus), especially the most common strains of HIV-1. HIV-1 is associated with the outbreak of AIDS.

5 The invention also relates to a diagnostic agent containing peptides, nucleic acids or antibodies of the invention. The diagnostic agent may be used for assay systems for testing isolated plasma, serum, tissue, urine and cerebrospinal fluid levels for HIV infections.

10 The invention also relates to assay systems which involve peptides of the invention as a tool to identify substances which bind to the envelope protein gp41 of HIV, in particular the N-terminal fusion peptide of gp41. Such assays can be any system which is suitable to measure the binding of any substance to the fusion peptide either integrated in the entire gp41 protein in isolated, viral, or any other form, or in synthetic form with a length up to 35 amino acid residues starting with the very N-terminus of gp41. In such assays, which can
15 be any spectroscopical, cellular, or radio-ligand assay, the binding of a substance in competition to peptides of the invention is measured. As a result of such competition assays using peptides of the invention as a tool, the identification of substances with increased affinity and binding site specificity to HIV gp41 is achieved. Such substances have an improved potency to block
20 cellular infection by HIV particles. They can be used as improved therapeutic agents to cure AIDS.

After synthesis of the various peptides of the present invention, yields were examined. For all peptides good yields were achieved (see table 1), reflecting the ease of the synthesis process. The peptides of the present invention were
25 subjected to various tests.

First, human cells were exposed to the peptides of the present invention in order to test their cytotoxicity. All peptides that were tested, namely VIR-161 (SEQ ID NO. 3), VIR-162 (SEQ ID NO. 4), VIR-163 (SEQ ID NO. 5), VIR-164
30 (SEQ ID NO. 6), VIR-165 (SEQ ID NO. 7), VIR-166 (SEQ ID NO. 8), VIR-170 (SEQ ID NO. 9), VIR-175 (SEQ ID NO. 10), VIR-182 (SEQ ID NO. 11), VIR-184 (SEQ ID NO. 12), VIR-190 (SEQ ID NO. 13), VIR-191 (SEQ ID NO. 14), VIR-192 (SEQ ID NO. 15), VIR-193 (SEQ ID NO. 16), VIR-197 (SEQ ID NO.

17), VIR-199 (SEQ ID NO. 18), VIR-229 (SEQ ID NO. 19), VIR-234 (SEQ ID NO. 20), VIR-243 (SEQ ID NO. 21), VIR-252 (SEQ ID NO. 22), VIR-255 (SEQ ID NO. 23), VIR-257 (SEQ ID NO. 24), VIR-258 (SEQ ID NO. 25), VIR-259 (SEQ ID NO. 26), VIR-260 (SEQ ID NO. 27), VIR-261 (SEQ ID NO. 28),
5 VIR-262 (SEQ ID NO. 29), VIR-263 (SEQ ID NO. 30), VIR-264 (SEQ ID NO. 31), VIR-265 (SEQ ID NO. 32), VIR-266 (SEQ ID NO. 33), VIR-268 (SEQ ID NO. 34), VIR-269 (SEQ ID NO. 35) were free of any cytotoxic effect. These data strongly suggest, that also those peptides not tested yet are non-cytotoxic.

10 The second set of experiments concerned the efficacy of the peptides of the present invention to inhibit HIV infection (see table 2). The peptides were tested on two HIV-1 strains and IC_{50} values were calculated. The most active peptides had an IC_{50} of equal or below 800 nM, whereby for example VIR-484
15 (SEQ ID NO. 79) had an IC_{50} of 100 nM. Peptides with still considerable activity where those with an IC_{50} of equal or below 2000 nM, and those with an IC_{50} of equal or below 6500 nM still had an increased activity in comparison to the native VIRIP (SEQ ID NO. 1); the native VIRIP (SEQ ID NO. 1) was found to have an IC_{50} of 15,000 or 22,000, if tested with HIV strains NL4-3 or
20 DTV, respectively. To summarise table 2, the peptides of the present invention displayed a 4-fold to 161-fold increase in anti-HIV activity in comparison to the native VIRIP.

The third set of experiments determined the *in vivo* toxicity of the VIRIP peptides of the present invention. Considering the positive outcome of the *in*
25 *vitro* cytotoxicity test, it was sufficient to test only one compound. Mice were injected with VIR-121 (SEQ ID NO. 2), observed over a period before sacrificing them. Throughout the life of the mice no signs of reduced or increased motility, dyspnea, ataxia, nor a reduced or increased muscle tone were observed. No changes of behaviour were observed, and behaviour was
30 comparable to that of the control animals. The pathological examination did not reveal any abnormalities. It was therefore concluded that the peptides of the present invention are well tolerated by a living organism.

A forth set of experiments concerned the stability of the peptides of the

present invention in mammalian plasma (see table 3). Plasma isolated from various animals and humans was spiked with defined amounts of various peptides of the present invention. The peptides displayed a considerable half life in human plasma, most prominent being VIR-512 (SEQ ID NO. 83), VIR-580 (SEQ ID NO. 87) and VIR-357 (SEQ ID NO. 60), with a half-life of 315 h, 38.9 h and 23.3 h, respectively. These peptides also showed considerable stability in the animal plasma, but the actual values varied from those found for human plasma. The native VIRIP (SEQ ID NO. 1) has a half-life of 53.7 h in human plasma. The results also showed, that rat plasma is not a suitable model system for these type of experiments.

In the final set of experiments the ability of peptides of the invention to interact with the fusion peptide of gp41 by measuring the suppression of the fusion peptide-induced hemolysis upon addition of increasing doses of peptides of the invention was tested. All peptides tested were more efficient in inhibiting the hemolytic effect of the fusion peptide than the native VIRIP. It was concluded that peptides of the invention change structural properties of the fusion peptide by specific interaction.

In essence, the peptides of the present invention are characterised by their anti-HIV activity, which, expressed as IC_{50} , is equal to or below 6500 nM, whereby the most active peptides have an IC_{50} of below 800 nM. Individual peptides of the present invention were found to have IC_{50} of below 100 nM (see table 1).

Examples

In total over 600 peptides were synthesised, of which only 84 are presented here in more detail (see table 1). Not every experiment was conducted with each peptide. Those 84 peptides presented here were more active against HIV as judged by their IC_{50} , than the remaining peptides. However, the 22 most active peptides of the group of 84 peptides were further selected, and subjected to an additional anti-viral activity test, using a different HIV strain. The most promising candidates of that screening were subjected to a plasma

stability test. A detailed description of the performed experiments is given below.

Example 1: Chemical synthesis of peptides of the present invention[KAD1]

5 The peptides according to the invention were chemically synthesized utilizing the principle of solid-phase peptide synthesis and the Fmoc or Boc protective group strategy (Atherton and Sheppard, 1989, Solid Phase Peptide Synthesis, IRL Press; Merrifield, 1986, Solid phase synthesis, Science 232, 341-347), but can also be synthesized with solution phase synthesis or by coupling protected
10 or unprotected fragments of the peptides according to the invention.

As an example, the synthesis of the peptide VIR-199 (amino acid sequence: LEAIPMSIPpEFLFNKPFVF) (SEQ ID NO. 18) is described here using fluorenylmethoxycarbonyl (Fmoc)-protected amino acids on an automated peptide synthesizer 433A (Applied Biosystems). The synthesis was performed
15 using a preloaded Fmoc-Phe-Wang resin with a loading capacity of 1 mmol/g resin with standard HBTU [(2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium-hexafluorophosphate)]/HOBt (1-hydroxybenzotriazol) activation with capping cycles using acetic anhydride in N-methylpyrrolidinone (NMP) at a scale of 0.2 mmol. The side chains of the amino acid building
20 blocks used were protected as follows: Glu(OtBu), Ser(tBu), Lys(Boc), Asn(Trt). Acylation steps for peptide chain assembly were carried out for 15-60 min, and Fmoc groups were deprotected with piperidine in NMP after each acylation. After deprotection of the leucine residue at position 1, the resulting protected peptidyl resin was washed with NMP, 2-propanol and
25 dichloromethane and then dried. The dry resin was treated at room temperature with a fresh mixture of trifluoroacetic acid/ethanedithiole/water (94:3:3, vol/vol/vol, 40 ml/g resin) for 2-4.5 h. The mixture was filtrated into ice-cold tert-butylmethylether (TBME) to facilitate precipitation of the peptide. The resulting precipitate was separated by centrifugation, washed with TBME
30 and dried under vacuum. The crude peptide was dissolved in diluted acetic acid and loaded onto a preparative Vydac C18 column (47x300 mm, 15-20 µm, flow rate 40 ml/min; solvent A, 0.07 volume % TFA; solvent B, 0.07 volume % TFA in acetonitrile/H₂O 80:20 (volume %); UV detection at 215 nm;

with the following gradient: 45-70 volume % B in 50 min. The fractions containing the desired pure peptide, as detected by mass spectrometry (API 100, Perkin Elmer) and analytical C18 HPLC or, alternatively, capillary zone electrophoresis, were pooled and dried by lyophilization. The lyophilized peptide was used for analysis of purity and molecular weight by analytical C18 HPLC (Figure 1), capillary zone electrophoresis, and mass spectrometry (Figure 2). The yield of the peptide LEAIPMSIPpEFLFNKPFVF (SEQ ID NO. 18) was 138 mg.

The process for synthesis of the peptides according to the invention was adapted to larger scales ranging from 0.5 to 20 mmol yielding purified peptides of the present invention in amounts between 1 g and 5 g. The synthesis process was also adapted to small-scale multiple peptide synthesis. Peptides according to the invention having intramolecular disulfide bonds were treated with air at pH 7.5-8.5, with or without dimethylsulfoxide, or alternatively, from linear precursors with two acetamidomethyl-protected cysteine residues by iodine oxidation to facilitate cysteine bridge formation. Using these general synthetic approaches, the following peptides, among others, were synthesized, purified by chromatographic methods to a degree of up to 98% and analysed:

Table 1: Yields and molecular weight of synthetic peptides. Yields are obtained from synthesis at various scales.

<u>Peptide</u>	<u>Yield</u> [mg]	<u>Molecular weight</u> (calculated)	<u>Molecular weight</u> (determined by mass spectrometry)
VIR-121	109	2246.7	2246.5
VIR-161	34	2190.6	2190.3
VIR-162	56	2119.6	2119.0
VIR-163	98	2232.7	2232.8
VIR-164	35	2266.7	2266.5
VIR-165	72	2238.7	2238.0

VIR-166	37	2361.4	2362.3
VIR-170	50	2265.7	2267.0
VIR-175	105	2279.7	2279.5
VIR-182	56	2217.6	2217.2
VIR-184	82	2260.7	2260.4
VIR-190	71	2175.6	2175.2
VIR-191	25	2231.7	2231.8
VIR-192	53	2265.7	2265.0
VIR-193	138	2294.7	2295.0
VIR-197	50	2322.7	2322.3
VIR-199	138	2336.8	2336.5
VIR-229	58	2228.6	2228.3
VIR-234	78	2216.6	2217.0
VIR-243	34	2312.7	2312.7
VIR-252	142	2290.7	2290.3
VIR-255	56	2303.7	2303.5
VIR-257	151	2329.0	2328.2
VIR-258	50	2345.0	2344.4
VIR-259	110	2312.9	2312.4
VIR-260	162	2324.0	2323.4
VIR-261	79	2371.0	2370.3
VIR-262	61	2234.6	2334.3
VIR-263	147	2334.6	2334.3
VIR-264	102	2379.1	2378.5
VIR-265	118	2329.0	2330.0
VIR-266	175	2361.8	2361.2
VIR-268	123	2308.5	2308.3
VIR-269	46	2301.0	2300.3
VIR-272	44	2306.8	2306.5
VIR-273	21	2340.8	2340.3
VIR-274	24	2249.7	2249.0
VIR-280	15	2223.7	2223.0

VIR-284	34	2247.7	2247.3
VIR-286	32	2199.7	2199.3
VIR-290	44	2247.7	2247.3
VIR-298	35	2343.8	2342.8
VIR-320	37	2235.7	2235.3
VIR-322	45	2292.8	2291.8
VIR-323	44	2306.8	2306.3
VIR-326	43	2260.7	2260.8
VIR-328	49	2331.8	2331.8
VIR-344	7	2209.8	2209.7
VIR-345	19	2223.7	2223.0
VIR-346	34	2161.6	2161.0
VIR-348	5	2119.6	2119.0
VIR-350	13	2211.7	2210.5
VIR-351	32	2238.7	2238.5
VIR-352	23	2266.8	2266.5
VIR-353	17	2280.8	2280.0
VIR-354	26	2190.7	2190.7
VIR-355	18	2160.6	2160.0
VIR-356	14	2256.7	2256.0
VIR-357	26	2234.7	2234.3
VIR-358	24	2247.7	2248.0
VIR-376	53	2350.8	2350.3
VIR-377	53	2336.8	2336.3
VIR-380	46	2426.9	2427.0
VIR-384	43	2408.9	2408.3
VIR-396	38	2237.7	2237.0
VIR-400	40	2313.8	2314.3
VIR-416	36	2249.7	2249.3
VIR-418	40	2306.8	2306.5
VIR-445	30	2316.7	2316.8
VIR-447	37	2290.6	2289.8

VIR-448	31	2304.7	2304.3
VIR-449	27	2304.7	2304.8
VIR-452	28	2378.8	2378.3
VIR-454	37	2391.8	2391.8
VIR-455	25	2391.8	2391.8
VIR-479	36	2332.8	2332.3
VIR-483	35	2343.7	2344.0
VIR-484	25	2343.7	2343.8
VIR-485	42	2317.7	2317.8
VIR-487	34	2330.7	2330.3
VIR-488	36	2304.6	2304.5
VIR-512	37	2293.6	2293.3
VIR-568	13	2257.7	2257.3
VIR-570	21	2205.6	2205.3
VIR-576*	12	4501.4	4502.0
VIR-580	41	2569.2	2568.5
VIR-590	41	2321.6	2320.8
VIRIP	265	2303.8	2303.6

* VIR-576 is a homo-dimer; an intermolecular disulfide bridge occurs at the cysteine at amino acid position 6.

5 Example 2: Cytotoxicity of the peptides of present invention on human cells

The cytotoxicity of peptides of the invention was tested by evaluating the viability of human monocytic THP-1 cells. Cytotoxic effects of the peptides were tested by their influence on metabolic activity by means of the WST-1 assay (Roche Diagnostics, Germany). THP-1 cells were incubated with test
10 peptides in a 96-well plate (approx. 25,000 cells per well) for 24 hours in RPMI-1640 medium containing 25 mM L-glutamine and 10 volume % fetal calf serum at 37 °C in an atmosphere with 5 volume % CO₂. Ten µl of a WST-1 solution was added to each cavity, and incubation of THP-1 cells was allowed for 2 further hours at corresponding conditions. Metabolically active THP-1

cells reduce WST-1, a light red tetrazolium salt, yielding a soluble yellow formazan salt. The amount of reduced WST-1 correlates directly to the number of living cells, and is measured photometrically at a wavelength of $\lambda = 450$ nm using a microtiter plate reader (reference wavelength is 630 nm). As a positive control, the known cytotoxic substance cycloheximide was used at a concentration of 50 $\mu\text{g/ml}$; the cytotoxicity of cycloheximide was set to 100%. As another positive control the peptide MBI-28, a highly cytotoxic peptide known to the skilled person, was used with a maximum concentration of 300 $\mu\text{g/ml}$. As a negative control, cultured THP-1 cells not treated with the peptides of the invention or a positive control were used. The cytotoxicity of VIRIP peptides was calculated using the formula

$$\text{Viability [\%]} = [A_{450 \text{ nm}} (\text{peptide}) - A_{450 \text{ nm}} (\text{cycloheximide})] / [A_{450 \text{ nm}} (\text{negative control}) - A_{450 \text{ nm}} (\text{cycloheximide})] * 100$$

and was correlated to the averaged viability of untreated THP-1 cells. The experiments were carried out at concentrations of peptides according to the invention of 30 $\mu\text{g/ml}$, 100 $\mu\text{g/ml}$, 300 $\mu\text{g/ml}$ and 1000 $\mu\text{g/ml}$. The peptides VIR-161 (SEQ ID NO. 3), VIR-162 (SEQ ID NO. 4), VIR-163 (SEQ ID NO. 5), VIR-164 (SEQ ID NO. 6), VIR-165 (SEQ ID NO. 7), VIR-166 (SEQ ID NO. 8), VIR-170 (SEQ ID NO. 9), VIR-175 (SEQ ID NO. 10), VIR-182 (SEQ ID NO. 11), VIR-184 (SEQ ID NO. 12), VIR-190 (SEQ ID NO. 13), VIR-191 (SEQ ID NO. 14), VIR-192 (SEQ ID NO. 15), VIR-193 (SEQ ID NO. 16), VIR-197 (SEQ ID NO. 17), VIR-199 (SEQ ID NO. 18), VIR-229 (SEQ ID NO. 19), VIR-234 (SEQ ID NO. 20), VIR-243 (SEQ ID NO. 21), VIR-252 (SEQ ID NO. 22), VIR-255 (SEQ ID NO. 23), VIR-257 (SEQ ID NO. 24), VIR-258 (SEQ ID NO. 25), VIR-259 (SEQ ID NO. 26), VIR-260 (SEQ ID NO. 27), VIR-261 (SEQ ID NO. 28), VIR-262 (SEQ ID NO. 29), VIR-263 (SEQ ID NO. 30), VIR-264 (SEQ ID NO. 31), VIR-265 (SEQ ID NO. 32), VIR-266 (SEQ ID NO. 33), VIR-268 (SEQ ID NO. 34), VIR-269 (SEQ ID NO. 35), were tested. These peptides did not exhibit a cytotoxic effect on monocytic THP-1 cells compared to the positive controls cycloheximid and MBI-28.

Example 3: Inhibition of the HIV infection by the peptides of present invention

P4-CCR5 indicator cells (Charneau et al., 1994; Journal of Molecular Biology 241, 651-662) expressing the primary CD4 receptor and both major HIV-1 entry cofactors CXCR4 and CCR5, were used to evaluate whether peptides according to the invention are potent inhibitors of HIV-1 infection. These cells contain the β -galactosidase reporter gene under the control of the HIV-1 promoter. Thus, activation of the β -galactosidase reporter gene allows to measure the efficiency of HIV-1 infection and thus to quantitate the potency of HIV-1 inhibitors (Detheux M. et al., 2000; Journal of Experimental Medicine 192, 1501-1508; Münch et al., 2002; Antimicrobial Agents and Chemotherapy 46, 982-990).

To perform a typical infection assay, P4-CCR5 cells (Charneau et al., 1994; Journal of Molecular Biology 241, 651-662; Charneau et al., Virology. 1994 205, 247-53) were kept in RPMI 1640 medium supplemented with 10 volume % FCS. This cell line coexpresses CD4 and both HIV-1 coreceptors CCR5 and CXCR4 and contains the β -galactosidase gene under the control of the HIV-1 promoter. Virus stocks were generated by the calcium coprecipitation method as described (Detheux et al., J Exp Med. 192:1501-8; 2000), and the p24 antigen levels were quantitated with an HIV p24 ELISA kit obtained through the NIH AIDS Reagent Program. Cells were seeded in flat-bottomed 96-well dishes, cultured overnight, and incubated with the different doses of peptide for 2 h before infection with virus containing 1 ng of p24 antigen in a total volume of 50 ml of medium. After overnight incubation, cells were washed twice and cultivated in fresh culture medium without inhibitory peptide. Three days after infection the cells were lysed, and infectivity was quantitated using the Galacto-Light Plus™ chemiluminescence reporter assay kit (Tropix, Bedford, MA) as recommended by the manufacturer. All infections were performed in quintuplicate.

The results of this assay demonstrate that peptides according to the invention have greatly enhanced anti-HIV-1 activity as compared to VIRIP. Peptides of the invention inhibited the infection by the X4-tropic HIV-1 NL4-3 and the HIV-1 NL4-3 DTV (from hereon called DTV) - DTV is a variant of NL4-3 and was originally described by Rimsky et al. (Journal of Virology 72, 986-993; 1998) as r4 - molecular clones with more than 10-fold up to more than 100-fold higher efficiency than the original VIRIP. Peptides of the invention were also active against infection by the R5-tropic HIV-1 YU-2 molecular clone. These data demonstrate that the specific modifications of VIRIP greatly enhance the anti-HIV-1 potency of peptides according to the invention. Below, the IC₅₀ values of peptides of the invention obtained from the described infection assay are provided.

Table 2: Amino acid sequence and anti-HIV activity

Peptide	Amino acid sequence	SEQ	IC ₅₀	IC ₅₀
		ID NO.	NL4-3	DTV
			[nM]	[nM]
VIR-121	LEAIPMSIPpEVAFNKPFVF	2	370	1790
VIR-161	LEAIPCSIPpCVAFNKPFVF	3	550	570
VIR-162	LEAIPCSIPPCVGFGKPFVF	4	660	950
VIR-163	LEAIPCSIPPCVLFNKPFVF	5	760	290
VIR-164	LEAIPCSIPPCVFFNKPFVF	6	340	370
VIR-165	LEAIPCSIPPCFAFNKPFVF	7	270	140
VIR-166	LEAIPCSIPPCVA(D-Tic)NKP(D-Tic)FVF	8	356	506
VIR-170	LEAIPMSIPPEVFFGKPFVF	9	1520	2000
VIR-175	LEAIPMSIPPEFLFGKPFVF	10	225	300
VIR-182	LEAIPMSIPPELAFAPKPFVF	11	2250	2970
VIR-184	LEAIPMSIPPEIAFNKPFVF	12	1990	5390
VIR-190	LEAIPMSIPpEVGFGKPFVF	13	1840	3110
VIR-191	LEAIPMSIPpEVLFKGKPFVF	14	1790	560
VIR-192	LEAIPMSIPpEVFFGKPFVF	15	1540	1210
VIR-193	LEAIPMSIPpEFAFNKPFVF	16	1740	1380

VIR-197	LEAIPMSIPpEVFFNKPFVF	17	1270	1440
VIR-199	LEAIPMSIPpEFLFNKPFVF	18	2140	1650
VIR-229	LEAIPISIPpEVAFNKPFVF	19	1280	2260
VIR-234	LEAIPMGIPpEVAFNKPFVF	20	740	6410
VIR-243	LEAIPMSIPPEFAFNKDFVF	21	2160	1980
VIR-252	LEDIPMSIPpEVAFNKPFVF	22	1750	1870
VIR-255	LEKIPMSIPpEVAFNKPFVF	23	650	1230
VIR-257	LEAIPMSIPpEV(cyclohexylalanine)FNKPFVF	24	860	660
VIR-258	LEAIPMSIPpE(1-naphthylalanine)AFNKPFVF	25	640	620
VIR-259	LEAIPMSIPpE(p-fluorophenylalanine)AFNKPFVF	26	860	1030
VIR-260	LEAIPMSIPpEV(4-pyridylalanine)FNKPFVF	27	2150	2380
VIR-261	LEAIPMSIPpE(3,3-diphenylalanine)AFNKPFVF	28	538	1029
VIR-262	LEAIPMSIPpEV(D-Tic)FNKPFVF	29	940	580
VIR-263	LEAIPMSIPpEV(L-Tic)FNKPFVF	30	770	330
VIR-264	LEAIPMSIPpEV(3-benzothienylalanine)FNKPFVF	31	590	700
VIR-265	LEAIPMSIPpEV(3-thienylalanine)FNKPFVF	32	1290	2210
VIR-266	LEAIPMSIPpEVWFNKPFVF	33	590	830
VIR-268	LEAIPMSIPpEVAFNK(L-Tic)FVF	34	1730	1480
VIR-269	LEAIPMSIPpEVAFNK(Oic)FVF	35	2610	900
VIR-272	LEAIPMCIPPECLFNKPFVF	36	999	
VIR-273	LEAIPMCIPPECFFNKPFVF	37	332	1102
VIR-274	LEAIPMCIPPECLFGKPFVF	38	576	1421
VIR-280	LEAIPCSIPPCFLFGKPFVF	39	93	
VIR-284	LEAIPISIPPEVFFGKPFVF	40	281	
VIR-286	LEAIPISIPPELAFAPKPFVF	41	559	
VIR-290	LEAIPISIPpEVFFGKPFVF	42	562	
VIR-298	LEAIPISIPpEVWFNKPFVF	43	969	
VIR-320	LEAIPMGIPpEVFFGKPFVF	44	277	
VIR-322	LEAIPMGIPpEVFFNKPFVF	45	836	
VIR-323	LEAIPMGIPpEFLFNKPFVF	46	924	
VIR-326	LEDIPMGIPpEVAFNKPFVF	47	963	
VIR-328	LEAIPMGIPpEVWFNKPFVF	48	685	

VIR-344	LEAIPCSIPPCVFFGKPFVF	49	348	448
VIR-345	LEAIPCSIPPCFLFGKPFVF	50	298	376
VIR-346	LEAIPCSIPPCLAFAKPFVF	51	541	
VIR-348	LEAIPCSIPpCVGFGKPFVF	52	326	541
VIR-350	LEAIPCSIPpCVFFGKPFVF	53	198	
VIR-351	LEAIPCSIPpCFAFNKPFVF	54	203	
VIR-352	LEAIPCSIPpCVFFNKPFVF	55	340	624
VIR-353	LEAIPCSIPpCFLFNKPFVF	56	225	181
VIR-354	LEAIPCSIPpCVAFNKPFVF	57	619	
VIR-355	LEAIPCGIPpCVAFNKPFVF	58	582	
VIR-356	LEAIPCSIPPCFAFNKDFVF	59	700	
VIR-357	LEDIPCSIPpCVAFNKPFVF	60	497	704
VIR-358	LEKIPCSIPpCVAFNKPFVF	61	706	944
VIR-376	LEAIPMSIPpEFLFGKPAFVF	62	568	
VIR-377	LEAIPMSIPpEFLFGKPGFVF	63	487	
VIR-380	LEAIPMSIPpEFLFGKPFVF	64	540	
VIR-384	LEAIPMSIPpEFLFGKPEFVF	65	622	
VIR-396	LEAIPMSAPpEFLFGKPFVF	66	628	
VIR-400	LEAIPMSFPpEFLFGKPFVF	67	590	
VIR-416	LEAIPMGIPpEFLFGKPFVF	68	369	
VIR-418	LEKIPMGIPpEFLFGKPFVF	69	500	
VIR-445	LEAIPISIPpEV(D-Tic)FNKPFVF	70	224	
VIR-447	LEAIPISIPpEVAFNK(L-Tic)FVF	71	620	
VIR-448	LEAIPMGIPpEV(D-Tic)FNKPFVF	72	318	325
VIR-449	LEAIPMGIPpEV(L-Tic)FNKPFVF	73	274	240
VIR-452	LEDIPMSIPpEV(L-Tic)FNKPFVF	74	184	
VIR-454	LEKIPMSIPpEV(D-Tic)FNKPFVF	75	464	1089
VIR-455	LEKIPMSIPpEV(L-Tic)FNKPFVF	76	134	353
VIR-479	LEDIPIGIPpEFLFNKPFVF	77	479	
VIR-483	LEKIPIGIPpEV(D-Tic)FNKPFVF	78	765	866
VIR-484	LEKIPIGIPpEV(L-Tic)FNKPFVF	79	100	339
VIR-485	LEKIPIGIPpEVAFNK(L-Tic)FVF	80	760	

VIR-487	LEDIPIGIPpEV(L-Tic)FNKPFVF	81	256	
VIR-488	LEDIPIGIPpEVAFNK(L-Tic)FVF	82	415	
VIR-512	<i>N-Me</i> -LEAIPMSIPPEFLFGKPFVF	83	138	615
VIR-568	LEAIPMSCPPEFCFGKPFVF	84	367	552
VIR-570	LEAIPCSIPPECLFGKPFVF	85	231	
VIR-576*	(LEAIPCSIPPEFLFGKPFVF) ₂	86	107	296
VIR-580	LEAIPMSIPPEFLFGKPFVF-miniPEG	87	150	497
VIR-590	LEAIPMKIPPEFLFGKPFVF	88	343	
VIRIP	LEAIPMSIPPEVKFNKPFVF	1	15000	22200

* VIR-576 is a homo-dimer; an intermolecular disulfide bridge occurs at the cysteine at amino acid position 6.

Example 4: Toxicity of the peptides of the present invention in mice

5

Acute toxicity was evaluated with VIR-121 (LEAIPMSIPpEVAFNKPFVF) after a single intravenous injection into the tail vein of SCID-C.B 17-mice. A dose of 927 mg VIR-121 (SEQ ID NO. 2) dissolved in 13.6 ml 0.9 volume % sodium chloride solution per kg body weight (equivalent to 20.4 mg or 272 μ L per mouse) was applied. Injection speed was dose within 15 seconds. Three animals were treated with the test substance, and the animals were observed at time points of 5, 15, 30 min, and 1, 3, 6, and 24 hours after administration of the sample into the tail vein. As a control, 3 mice were each treated with a corresponding volume of vehicle (0.9 volume % NaCl). After 24 hours, the animals were sacrificed, dissected and inspected macroscopically. During and after application until the end of the observation period of 24 hours for all animals treated with VIR-121 (SEQ ID NO. 2) no signs of reduced or increased motility, dyspnea, ataxia, nor a reduced or increased muscle tone were observed. No changes of behaviour was observed, and behaviour was comparable to that of the control animals. No findings were obtained from macroscopic necropsy compared to the control group.

Example 5: Stability of peptides of the invention in mammalian plasma

To evaluate the half-life and exposure of peptides of the invention, the stability of peptides was examined in mammalian plasma after incubation in EDTA plasma obtained from human, dog, cynomolgus and rat at 37 °C. Plasma was spiked resulting in concentrations of 40 µg/ml and stored at 37 °C. At time points 0, 15, 30, 45, 60, 120, 180, 240 and 300 min samples of 20 µl were taken. The plasma was immediately mixed for precipitation with the two-fold volume of acetonitrile containing 0.15% (w/v) *n*-nonyl- α -D-glucopyranoside. Following centrifugation the supernatants were mixed with the two-fold volume of 0.1% (v/v) trifluoroacetic acid. Twenty µl of these solutions were analyzed by LC-MS. Chromatography was performed using a gradient with the following eluents: eluent A: water containing 0.06% trifluoroacetic acid (v/v), eluent B: acetonitrile/water 80:20 (v/v; with 0.05% trifluoroacetic acid; v/v). A C18 precolumn was used in combination with a C18 separation column (300 Å, 5 µm, 150 x 1 mm inner diameter) at a flow rate of 30 µl/min. HPLC eluates were ionized by the electrospray technique of a LCQ classic mass spectrometer. Areas of the detected peaks of the peptides of the present invention were measured and used for quantification by external calibration. The calibration curve was linear over a range from 0.5 µg/ml to 250 µg/ml plasma. Half life - defined as the period for a concentration decrease to 50% of the initial concentration - was calculated from the slope of an extrapolated curve plotting the relative peptide concentration at a given time point (logarithm scale) against the incubation time. These experiments allowed the quantitative analysis of peptide concentration in plasma. The results obtained show a considerable half-life of peptides of the invention in humans, cynomolgus monkeys and dogs, while in vitro half-life in the rat appears to be short. The values obtained for $t_{1/2}$ in humans and the monkey demonstrate that peptides of the invention exhibit a sufficient half-life required for the inhibition of cellular infection by HIV particles and thus for therapeutical use against AIDS. The following table shows the calculated half-life of peptides of the invention in the corresponding plasma of humans, rat, dog and cynomolgus monkey.

Table 3: Half-lives of the peptides of the present invention in plasma of human, rat, dog and cynomolgus monkey.

Peptide	<u>t_{1/2} human</u> [h]	<u>t_{1/2} rat</u> [h]	<u>t_{1/2} dog</u> [h]	<u>t_{1/2} cynomolgus</u> [h]
VIRIP	53.7	1.7	35.9	5.1
VIR-166	7.6	0.4	11	12.1
VIR-175	5.3	0.2	17.3	3
VIR-261	7	0.2	15.1	6.5
VIR-273	4.2	0.1	12.4	3.6
VIR-274	2	0.1	9.5	2.8
VIR-344	7	0.1	6.6	10.5
VIR-345	5.6	0.1	10.7	5.1
VIR-348	3.3	0.2	9.3	3
VIR-352	3.6	0.2	23.7	6.4
VIR-353	4	0.2	15.2	5
VIR-357	23.3	0.6	71.5	13.2
VIR-358	5.9	0.4	16	4.7
VIR-448	3.1	0.2	18	4.5
VIR-449	4.8	0.2	42.2	4.2
VIR-454	4.4	0.2	15.6	4.4
VIR-455	5.8	0.3	8.6	6.8
VIR-483	2.6	0.2	6.2	2.2
VIR-484	5	0.2	12.4	3.6
VIR-512	315	> 6	48.1	33.6
VIR-568	3.9	0.1	4	2.2
VIR-576	5.8	2.6	12.6	3.8
VIR-580	38.9	1.4	42	10.2

5

Example 6: Inhibition of fusion peptide-induced hemolysis

The synthetic fusion peptide of HIV gp41 causes concentration-dependent hemolysis which can be measured by hemoglobin released by erythrocytes.

Peptides and any other substance binding to the fusion peptide impair its potency to lyse erythrocytes by changing its structural properties. The inhibition of fusion peptide induced hemolysis was tested as follows: Blood from healthy donors was collected in citrate monovettes and the erythrocytes were extracted by a standard centrifugation and washing protocol known to the skilled person. The final erythrocyte-containing pellet was diluted 1:100 with phosphate-saline buffer. To the peptides (10, 100, or 1000 equivalents) 20 µl of a 100 µM fusion peptide solution in 10% DMSO were added and the solution was diluted to 100 µl with phosphate-buffered saline. A 60 min incubation at 37 °C was carried out. After the preincubation the samples were transferred to 96-well plates and 100 µl of the erythrocyte suspension were added and incubated for 60 min at 37 °C. Total hemolysis was achieved with 1% Tween-20. The 96-well plate is centrifuged 5 min at 2800 rpm and of the supernatant fluid 150 µl were transferred to a flat-bottom microtiter plate, and the absorbance was measured at 450 nm. The percentage hemolysis was calculated by: $[(A_{450} \text{ of the peptide treated sample} - A_{450} \text{ of buffer treated sample}) / (A_{450} \text{ of Tween-20 treated sample} - A_{450} \text{ of buffer treated sample})] \times 100\%$.

The results show that the fusion peptide-induced hemolysis is inhibited upon addition of increasing concentrations of peptides of the invention. In particular, the fusion peptide-induced hemolysis is more effectively inhibited by peptides of the invention compared to VIRIP. These results demonstrate that peptides of the invention block cellular infection by HIV particles by interacting with the viral gp41 protein.

Abbreviations:

	AIDS:	acquired immuno-defincy syndrome
	Boc:	tert-butyloxycarbonyl
	CXCR4:	CXC chemokine receptor 4
5	CCR5:	CC chemokine recptor 5
	ESI-MS:	electrospray ionization-mass spectrometry
	FP:	fusion peptide
	HIV:	human immunodeficiency virus
	HPLC:	high performance liquid chromatography
10	HR-1, HR-2:	heptad repeat 1, 2
	MALDI-TOF:	matrix-assisted laser desorption/ionization-time-of-flight
	Mini-PEG:	-NH-(CH ₂) ₂ -O-(CH ₂) ₂ -O-CH ₂ -CO-NH-(CH ₂) ₂ -O-(CH ₂) ₂ -O-CH ₂ -CO-NH ₂
	NMR:	nuclear magnetic resonance
15	Oic:	octahydroindolyl-2-carboxylic acid
	PEG:	pegyl, polyoxyethyleneglycol
	QSAR:	quantitative structure-activity relationship
	tBu:	tert-butyl
	TFA:	trifluoroacetic acid
20	Tic:	1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
	Trt:	trityl

Claims

1. Peptides according to claim 1, with biological activity against infection by HIV, having the amino acid sequence

Z₁-LE-X₁-IP-X₂-X₃-X₄-P-X₅-X₆-X₇-X₈-X₉-X₁₀-K-X₁₁-X₁₂-X₁₃-X₁₄-X₁₅-Z₂,

wherein

X₁ is a lysine, alanine, or aspartic acid;

X₂ is a cysteine, methionine or isoleucine;

X₃ is a serine, cysteine, lysine or glycine;

X₄ is an isoleucine, alanine, phenylalanine or cysteine;

X₅ is a proline, D-proline or a substituted L-or D-proline;

X₆ is a cysteine or glutamic acid;

X₇ is an amino acid with a hydrophobic or an aromatic side chain or cysteine;

X₈ is an amino acid with a hydrophobic or an aromatic side chain or cysteine;

X₉ is an amino acid with an aromatic side chain;

X₁₀ is a glycine, alanine or asparagine;

X₁₁ is a proline, aspartic acid, octahydroindolyl-2-carboxylic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;

X₁₂ is a phenylalanine, alanine, glycine, glutamic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;

X₁₃ is an amino acid with a hydrophobic or an aromatic side chain;

X₁₄ is an amino acid with a hydrophobic or an aromatic side chain;

X₁₅ is a phenylalanine or deletion;

Z₁ is NH₂ or a sequence of 1 to 10 amino acid residues;

Z₂ is COOH or a sequence of 1 to 10 amino acid residues;

and peptides which are fragments and/or covalently linked oligomers and/or derivatives, especially amidated, alkylated, acylated, sulfated, pegylated, phosphorylated and/or glycosylated derivatives, and mutants thereof;

and with the proviso that

- (a) if X_{12} is alanine, glycine, glutamic acid, or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid than X_{13} , X_{14} and X_{15} are phenylalanine, valine and phenylalanine respectively; and/or
- (b) if X_{12} is phenylalanine, than X_{13} , X_{14} and X_{15} are valine, phenylalanine and a deletion, respectively; and
- (c) that there are at maximum two cysteine residues in a peptide.

2. Peptides according to claim 1 with a biological activity against infection by HIV having the amino acid sequence

Z_1 -LE- X_1 -IP- X_1 - X_3 - X_4 -P- X_5 - X_6 - X_7 - X_8 - X_9 - X_{10} -K- X_{11} -FVF- Z_2 ,
wherein

X_1 is a lysine, alanine or aspartic acid;

X_2 is a cysteine, methionine or isoleucine;

X_3 is a serine, cysteine or glycine;

X_4 is a isoleucine or cysteine;

X_5 is a proline, D-proline or any substituted L- or D-proline;

X_6 is a cysteine or glutamic acid;

X_7 is a phenylalanine, cysteine, valine, isoleucine or 3,3-diphenylalanine;

X_8 is a phenylalanine, leucine, alanine, glycine, cysteine, D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid or L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;

X_9 is an amino acid with an aromatic side chain;

X_{10} is a glycine or asparagine;

X_{11} is a proline or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic;

Z_1 is NH_2 or a sequence of 1 to 10 amino acid residues;

Z_2 is $COOH$ or a sequence of 1 to 10 amino acid residues;

and peptides which are fragments and/or covalently linked oligomers and/or derivatives, especially amidated, alkylated, acylated, sulfated, pegylated, phosphorylated and/or glycosylated derivatives, and mutants thereof,

with the proviso that

- (a) if two cysteine residues are present, said residues are separated by four other amino acid residues; and

(b) L-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid (L-Tic), D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (D-Tic) and/or 3,3-diphenylalanine are present, no cysteine residue is present.

- 5 3. Peptides according to claims 1 to 2 with a biological activity against infection by HIV, having the amino acid sequence
Z₁-LE-X₂-IP-X₂-X₃-IP-X₅-X₆-X₇-X₈-F-X₁₀-KPFVF-Z₂,
wherein
X₁ is a lysine, alanine or aspartic acid;
10 X₂ is a cysteine, methionine or isoleucine;
X₃ is a serine or glycine;
X₅ is a L-proline, D-proline or any substituted L- or D-proline
X₆ is a cysteine or glutamic acid;
X₇ is a phenylalanine or valine;
15 X₈ is a phenylalanine, leucine, alanine or L-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid;
X₁₀ is a glycine or asparagine;
Z₁ is NH₂ or a sequence of 1 to 10 amino acid residues;
Z₂ is COOH or a sequence of 1 to 10 amino acid residues, and
20 and peptides which are fragments and/or covalently linked oligomers and/or derivatives, especially amidated, alkylated, acylated, sulfated, pegylated, phosphorylated and/or glycosylated derivatives, and mutants thereof.
- 25 4. Peptides according to claim 1 to 3, having the amino acid sequence
Z₁-LEAIP-X₂-SIP-X₅-X₆-V-X₈-FNKPFVF-Z₂,
wherein
X₂ and X₆ are cysteines, or X₂ is methionine and X₆ is glutamic acid
X₅ is a D-proline or L-proline;
30 X₈ is an amino acid with a hydrophobic or an aromatic side chain or lysine;
Z₁ is NH₂ or a sequence of 1 to 10 amino acid residues;
Z₂ is COOH or a sequence of 1 to 10 amino acid residues;
and peptides which are fragments and/or covalently linked oligomers

and/or derivatives, especially amidated, alkylated, acylated, sulfated, pegylated, phosphorylated and/or glycosylated derivatives, and mutants thereof, with biological activity against infection by HIV, with the proviso that at least one of the following is true:

5 X₂ is D-proline or
X₅ is not lysine or
X₆ and X₈ are cysteine.

10 5. Peptides according to anyone of the claim 1 to 4, wherein the cysteine residues at positions 6 and 11, 6 and 12, 7 and 12, or 8 and 13 are connected by an intramolecular disulfide bond.

15 6. Peptides according to anyone of the claim 1 to 4, with a single cysteine residue, wherein said cysteine residue is connected by an intermolecular disulfide bond to another peptide with a single cysteine residue, forming a homo-dimer.

20 7. Peptides according to anyone of the claims 1 to 6, wherein the leucine residue at amino acid position 1 and the glutamic acid at amino acid position 2 are covalently linked by an N-alkylated amide bond or by an ester bond or by a reduced peptide bond or by a retro-inverso peptide bond or by an N-alkylated retro-inverso peptide bond.

25 8. Peptides according to any of the claims 1 to 7 with one of the amino acid sequences

VIR-121	LEAIPMSIPpEVAFNKPFVF	SEQ ID NO. 2
VIR-161	LEAIPCSIPpCVAFNKPFVF	SEQ ID NO. 3
30 VIR-162	LEAIPCSIPPCVGFGKPFVF	SEQ ID NO. 4
VIR-163	LEAIPCSIPPCVLFNKPFVF	SEQ ID NO. 5
VIR-164	LEAIPCSIPPCVFFNKPFVF	SEQ ID NO. 6
VIR-165	LEAIPCSIPPCFAFNKPFVF	SEQ ID NO. 7

	VIR-166	LEAIPCSIPPCVA(D-Tic)NKP(D-Tic)FVF	SEQ ID NO. 8
	VIR-170	LEAIPMSIPPEVFFGKPFVF	SEQ ID NO. 9
	VIR-175	LEAIPMSIPPEFLFGKPFVF	SEQ ID NO. 10
	VIR-182	LEAIPMSIPPELAFAKPFVF	SEQ ID NO. 11
5	VIR-184	LEAIPMSIPPEIAFNKPFVF	SEQ ID NO. 12
	VIR-190	LEAIPMSIPpEVGFGKPFVF	SEQ ID NO. 13
	VIR-191	LEAIPMSIPpEVLFGKPFVF	SEQ ID NO. 14
	VIR-192	LEAIPMSIPpEVFFGKPFVF	SEQ ID NO. 15
	VIR-193	LEAIPMSIPpEFAFNKPFVF	SEQ ID NO. 16
10	VIR-197	LEAIPMSIPpEVFFNKPFVF	SEQ ID NO. 17
	VIR-199	LEAIPMSIPpEFLFNKPFVF	SEQ ID NO. 18
	VIR-229	LEAIPISIPpEVAFNKPFVF	SEQ ID NO. 19
	VIR-234	LEAIPMGIPpEVAFNKPFVF	SEQ ID NO. 20
	VIR-243	LEAIPMSIPPEFAFNKDFVF	SEQ ID NO. 21
15	VIR-252	LEDIPMSIPpEVAFNKPFVF	SEQ ID NO. 22
	VIR-255	LEKIPMSIPpEVAFNKPFVF	SEQ ID NO. 23
	VIR-257	LEAIPMSIPpEV(cyclohexylalanine)FNKPFVF	SEQ ID NO. 24
	VIR-258	LEAIPMSIPpE(1-naphthylalanine)AFNKPFVF	SEQ ID NO. 25
	VIR-259	LEAIPMSIPpE(p-fluorophenylalanine)AFNKPFVF	SEQ ID NO. 26
20	VIR-260	LEAIPMSIPpEV(4-pyridylalanine)FNKPFVF	SEQ ID NO. 27
	VIR-261	LEAIPMSIPpE(3,3-diphenylalanine)AFNKPFVF	SEQ ID NO. 28
	VIR-262	LEAIPMSIPpEV(D-Tic)FNKPFVF	SEQ ID NO. 29
	VIR-263	LEAIPMSIPpEV(L-Tic)FNKPFVF	SEQ ID NO. 30
	VIR-264	LEAIPMSIPpEV(3-benzothienylalanine)FNKPFVF	SEQ ID NO. 31
25	VIR-265	LEAIPMSIPpEV(3-thienylalanine)FNKPFVF	SEQ ID NO. 32
	VIR-266	LEAIPMSIPpEVWFNKPFVF	SEQ ID NO. 33
	VIR-268	LEAIPMSIPpEVAFNK(L-Tic)FVF	SEQ ID NO. 34
	VIR-269	LEAIPMSIPpEVAFNK(Oic)FVF	SEQ ID NO. 35
	VIR-272	LEAIPMCIPPECLFNKPFVF	SEQ ID NO. 36
30	VIR-273	LEAIPMCIPPECFFNKPFVF	SEQ ID NO. 37
	VIR-274	LEAIPMCIPPECLFGKPFVF	SEQ ID NO. 38
	VIR-280	LEAIPCSIPPCFLFGKPFVF	SEQ ID NO. 39
	VIR-284	LEAIPISIPPEVFFGKPFVF	SEQ ID NO. 40

	VIR-286	LEAIPISIPPELAFKPFVF	SEQ ID NO. 41
	VIR-290	LEAIPISIPpEVFFGKPFVF	SEQ ID NO. 42
	VIR-298	LEAIPISIPpEVWFNKPFVF	SEQ ID NO. 43
	VIR-320	LEAIPMGIPpEVFFGKPFVF	SEQ ID NO. 44
5	VIR-322	LEAIPMGIPpEVFFNKPFVF	SEQ ID NO. 45
	VIR-323	LEAIPMGIPpEFLFNKPFVF	SEQ ID NO. 46
	VIR-326	LEDIPMGIPpEVAFNKPFVF	SEQ ID NO. 47
	VIR-328	LEAIPMGIPpEVWFNKPFVF	SEQ ID NO. 48
	VIR-344	LEAIPCSIPPCVFFGKPFVF	SEQ ID NO. 49
10	VIR-345	LEAIPCSIPPCFLFGKPFVF	SEQ ID NO. 50
	VIR-346	LEAIPCSIPPCLAFAKPFVF	SEQ ID NO. 51
	VIR-348	LEAIPCSIPpCVGFGKPFVF	SEQ ID NO. 52
	VIR-350	LEAIPCSIPpCVFFGKPFVF	SEQ ID NO. 53
	VIR-351	LEAIPCSIPpCFAFNKPFVF	SEQ ID NO. 54
15	VIR-352	LEAIPCSIPpCVFFNKPFVF	SEQ ID NO. 55
	VIR-353	LEAIPCSIPpCFLFNKPFVF	SEQ ID NO. 56
	VIR-354	LEAIPCSIPpCVAFNKPFVF	SEQ ID NO. 57
	VIR-355	LEAIPCGIPpCVAFNKPFVF	SEQ ID NO. 58
	VIR-356	LEAIPCSIPPCFAFNKDFVF	SEQ ID NO. 59
20	VIR-357	LEDIPCSIPpCVAFNKPFVF	SEQ ID NO. 60
	VIR-358	LEKIPCSIPpCVAFNKPFVF	SEQ ID NO. 61
	VIR-376	LEAIPMSIPpEFLFGKPAFVF	SEQ ID NO. 62
	VIR-377	LEAIPMSIPpEFLFGKPGFVF	SEQ ID NO. 63
	VIR-380	LEAIPMSIPpEFLFGKPFFVF	SEQ ID NO. 64
25	VIR-384	LEAIPMSIPpEFLFGKPEFVF	SEQ ID NO. 65
	VIR-396	LEAIPMSAPpEFLFGKPFVF	SEQ ID NO. 66
	VIR-400	LEAIPMSFPpEFLFGKPFVF	SEQ ID NO. 67
	VIR-416	LEAIPMGIPpEFLFGKPFVF	SEQ ID NO. 68
	VIR-418	LEKIPMGIPpEFLFGKPFVF	SEQ ID NO. 69
30	VIR-445	LEAIPISIPpEV(D-Tic)FNKPFVF	SEQ ID NO. 70
	VIR-447	LEAIPISIPpEVAFNK(L-Tic)FVF	SEQ ID NO. 71
	VIR-448	LEAIPMGIPpEV(D-Tic)FNKPFVF	SEQ ID NO. 72
	VIR-449	LEAIPMGIPpEV(L-Tic)FNKPFVF	SEQ ID NO. 73

	VIR-452	LEDIPMSIPpEV(L-Tic)FNKPFVF	SEQ ID NO. 74
	VIR-454	LEKIPMSIPpEV(D-Tic)FNKPFVF	SEQ ID NO. 75
	VIR-455	LEKIPMSIPpEV(L-Tic)FNKPFVF	SEQ ID NO. 76
	VIR-479	LEDIPIGIPpEFLFNKPFVF	SEQ ID NO. 77
5	VIR-483	LEKIPIGIPpEV(D-Tic)FNKPFVF	SEQ ID NO. 78
	VIR-484	LEKIPIGIPpEV(L-Tic)FNKPFVF	SEQ ID NO. 79
	VIR-485	LEKIPIGIPpEVAFNK(L-Tic)FVF	SEQ ID NO. 80
	VIR-487	LEDIPIGIPpEV(L-Tic)FNKPFVF	SEQ ID NO. 81
	VIR-488	LEDIPIGIPpEVAFNK(L-Tic)FVF	SEQ ID NO. 82
10	VIR-512	<i>N</i> -Me-LEAIPMSIPPEFLFGKPFVF	SEQ ID NO. 83
	VIR-568	LEAIPMSCPPEFCFGKPFVF	SEQ ID NO. 84
	VIR-570	LEAIPCSIPPECLFGKPFVF	SEQ ID NO. 85
	VIR-576	(LEAIPCSIPPEFLFGKPFVF) ₂	SEQ ID NO. 86
	VIR-580	LEAIPMSIPPEFLFGKPFVF-miniPEG	SEQ ID NO. 87
15	VIR-590	LEAIPMKIPPEFLFGKPFVF	SEQ ID NO. 88

9. The peptides according to anyone of claims 1 to 8, which interact with the fusion peptide of HIV.

20 10. The peptides according to anyone of claims 1 to 9, which have an IC₅₀ of equal or below 6500 nM, preferably those having an IC₅₀ of equal or below 2000 nM and most preferably those having an IC₅₀ of equal or below 800 nM such as VIR-344 (SEQ ID NO. 49) with an IC₅₀ of 348 nM, VIR-345 (SEQ ID NO. 50) with an IC₅₀ of 298 nM, VIR-353 (SEQ ID NO. 56) with an
25 IC₅₀ of 225 nM, VIR-357 (SEQ ID NO. 60) with an IC₅₀ of 497 nM, VIR-358 (SEQ ID NO. 61) with an IC₅₀ of 706 nM, VIR-449 (SEQ ID NO. 73) with an IC₅₀ of 274 nM, VIR-455 (SEQ ID NO. 76) with an IC₅₀ of 134 nM, VIR-484 (SEQ ID NO. 79) with an IC₅₀ of 100 nM, VIR-512 (SEQ ID NO. 83) with an IC₅₀ of 138 nM, VIR-576 (SEQ ID NO. 86) with an IC₅₀ of 107 nM and VIR-
30 580 (SEQ ID NO. 87) with an IC₅₀ of 150 nM.

11. Nucleic acids coding for peptides according to any of claims 1 to 10.

12. Antibodies binding specifically to peptides according to claims 1 to 10.

5 13. A medicament containing the peptides according to claims 1 to 10, nucleic acids of claim 11 or antibodies of claim 12.

14. The medicament of claim 13 in galenic formulations for oral, intravenous,
intramuscular, intracutaneous, subcutaneous, intrathecal administration,
10 and as an aerosol for transpulmonary administration.

15. The medicament of claim 13 or 14 comprising at least one further therapeutic agent.

15 16. The medicament of claim 15, wherein the said at least one further therapeutic agent is a viral protease inhibitor, a reverse transcriptase inhibitor, a fusion inhibitor, a cytokine, a cytokine inhibitor, a glycosylation inhibitor or a viral mRNA inhibitor.

20 17. Use of the peptides according to claims 1 to 10 for the manufacturing of a medicament for the treatment of HIV infections.

18. An assay for determining molecules capable of interaction with the fusion peptide of HIV, comprising a peptide according to anyone of claims 1 to
25 10.

19. Use of the peptides according to anyone of claims 1 to 10 in an assay according to claim 16.

30 20. A diagnostic agent containing peptides according to any of claims 1 to 10, nucleic acids according to claim 11 or antibodies according to claim 12.

21. Use of the diagnostic agent according to claim 18 for assay systems for

testing isolated plasma, tissue, urine and cerebrospinal fluid levels for HIV infection.

Abstract

The invention relates to peptides with biological activity against infection
5 having the amino acid sequence

Z_1 -LE- X_1 -IP- X_2 - X_3 - X_4 -P- X_5 - X_6 - X_7 - X_8 - X_9 - X_{10} -K- X_{11} - X_{12} - X_{13} - X_{14} - X_{15} - Z_2 ,

wherein

X_1 is a lysine, alanine, or aspartic acid;

X_2 is a cysteine, methionine or isoleucine;

10 X_3 is a serine, cysteine, lysine or glycine;

X_4 is an isoleucine, alanine, phenylalanine or cysteine;

X_5 is a proline, D-proline or a substituted L-or D-proline;

X_6 is a cysteine or glutamic acid;

X_7 is an amino acid with a hydrophobic or an aromatic side chain or cysteine;

15 X_8 is an amino acid with a hydrophobic or an aromatic side chain or cysteine;

X_9 is an amino acid with an aromatic side chain;

X_{10} is a glycine, alanine or asparagine;

X_{11} is a proline, aspartic acid, octahydroindolyl-2-carboxylic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;

20 X_{12} is a phenylalanine, alanine, glycine, glutamic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;

X_{13} is an amino acid with a hydrophobic or an aromatic side chain;

X_{14} is an amino acid with a hydrophobic or an aromatic side chain;

X_{15} is a phenylalanine or deletion;

25 Z_1 is NH_2 or a sequence of 1 to 10 amino acid residues;

Z_2 is $COOH$ or a sequence of 1 to 10 amino acid residues;

and peptides which are fragments and/or covalently linked oligomers and/or derivatives, especially amidated, alkylated, acylated, sulfated, pegylated, phosphorylated and/or glycosylated derivatives, and mutants thereof,

30 and with the proviso that


(a) if X_{12} is alanine, glycine, glutamic acid, or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid than X_{13} , X_{14} and X_{15} are phenylalanine, valine and phenylalanine respectively; and/or

- (b) if X_{12} is phenylalanine, than X_{13} , X_{14} and X_{15} are valine, phenylalanine and a deletion, respectively; and
- (c) that there are at maximum two cysteine residues in a peptide.

10/539627

-1/4-


Figure 1



10/539627


-2/4-

Figure 2



-3/4-


Figure 3



10/539627

-4/4-

Figure 4



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 July 2004 (08.07.2004)

PCT

(10) International Publication Number
WO 2004/056871 A3

(51) International Patent Classification⁷: **C07K 14/81**,
A61K 38/57, G01N 33/68, A61P 31/18, C12N 15/15

(21) International Application Number:
PCT/EP2003/014654

(22) International Filing Date:
19 December 2003 (19.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02028465.9 19 December 2002 (19.12.2002) EP

(71) Applicant (for all designated States except US): **IPF PHARMACEUTICALS** [DE/DE]; Feodor-Lynen-Str. 31, 30625 Hannover (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ADERMANN, Knut** [DE/DE]; Schleidenstrasse 5, 30177 Hannover (DE). **KIRCHHOFF, Frank** [DE/DE]; Schmiedgasse 21-3, 89077 Ulm (DE). **MÜNCH, Jan** [DE/DE]; Einsteinstr. 17-2, 89077 Ulm (DE). **SCHULZ, Axel** [DE/DE]; Schneiderberg 28, 30167 Hannover (DE).

(74) Agent: **MEYERS, Hans-Wilhelm**; P.O. Box 10 22 41, 50462 Cologne (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
21 October 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **PEPTIDES AND THEIR USE FOR THE TREATMENT OF HIV INFECTIONS**

(57) Abstract: The invention relates to peptides with biological activity against infection having the amino acid sequence Z₁-LE-X₁-IP-X₂-X₃-X₄-P-X₅-X₆-X₇-X₈-X₉-X₁₀-K-X₁₁-X₁₂-X₁₃-X₁₄-X₁₅-Z₂, wherein X₁ is a lysine, alanine, or aspartic acid; X₂ is a cysteine, methionine or isoleucine; X₃ is a serine, cysteine, lysine or glycine; X₄ is an isoleucine, alanine, phenylalanine or cysteine; X₅ is a proline, D-proline or a substituted L- or D-proline; X₆ is a cysteine or glutamic acid; X₇ is an amino acid with a hydrophobic or an aromatic side chain or cysteine; X₈ is an amino acid with a hydrophobic or an aromatic side chain or cysteine; X₉ is an amino acid with an aromatic side chain; X₁₀ is a glycine, alanine or asparagine; X₁₁ is a proline, aspartic acid, octahydroindolyl-2-carboxylic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; X₁₂ is a phenylalanine, alanine, glycine, glutamic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; X₁₃ is an amino acid with a hydrophobic or an aromatic side chain; X₁₄ is an amino acid with a hydrophobic or an aromatic side chain; X₁₅ is a phenylalanine or deletion; Z₁ is NH₂ or a sequence of 1 to 10 amino acid residues; Z₂ is COOH or a sequence of 1 to 10 amino acid residues; and peptides which are fragments and/or covalently linked oligomers and/or derivatives, especially amidated, alkylated, acylated, sulfated, pegylated, phosphorylated and/or glycosylated derivatives, and mutants thereof, and with the proviso that (a) if X₁₂ is alanine, glycine, glutamic acid, or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid than X₁₃, X₁₄ and X₁₅ are phenylalanine, valine and phenylalanine respectively; and/or (b) if X₁₂ is phenylalanine, than X₁₃, X₁₄ and X₁₅ are valine, phenylalanine and a deletion, respectively; and (c) that there are at maximum two cysteine residues in a peptide.

WO 2004/056871 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/14654

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/81 A61K38/57 G01N33/68 A61P31/18 C12N15/15

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K G01N C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/34640 A (ADERMANN KNUT ;KIRCHHOFF FRANK (DE); MUENCH JAN (DE); FORSSMANN WO) 17 May 2001 (2001-05-17) page 2, paragraph 3; claims; examples page 2, last paragraph - page 3, paragraph 4 page 4, paragraph 3	1-4, 11-15
X	SHAPIRO LELAND ET AL: "Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1" FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US, vol. 15, no. 1, January 2001 (2001-01), pages 115-122, XP002164955 ISSN: 0892-6638 page 120, left-hand column, last paragraph - right-hand column, paragraph 5 ----- -/-	1-4, 13-15

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

25 August 2004

Date of mailing of the international search report

01/09/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Fuhr, C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/14654

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 92/18141 A (UAB RESEARCH FOUNDATION) 29 October 1992 (1992-10-29) figure 1	1-4
X	WO 01/08708 A (UNIV CASE WESTERN RESERVE ; MALOUF ALFRED (US); ZIADY ASSEM (US); DAVI) 8 February 2001 (2001-02-08) page 2, line 4; sequence 2 page 5, line 20 - line 24	1-4

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/14654

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0134640	A	17-05-2001	DE 19953732 A1	17-05-2001
			DE 10023665 A1	22-11-2001
			AU 2354801 A	06-06-2001
			CA 2390652 A1	17-05-2001
			WO 0134640 A2	17-05-2001
			EP 1228203 A2	07-08-2002
			JP 2003516729 T	20-05-2003
WO 9218141	A	29-10-1992	CA 2108689 A1	19-10-1992
			EP 0616614 A1	28-09-1994
			JP 6509327 T	20-10-1994
			WO 9218141 A1	29-10-1992
			US 5668107 A	16-09-1997
			US 5420110 A	30-05-1995
WO 0108708	A	08-02-2001	AU 6239700 A	19-02-2001
			CA 2391348 A1	08-02-2001
			EP 1200616 A2	02-05-2002
			JP 2003505518 T	12-02-2003
			WO 0108708 A2	08-02-2001
			US 2004152653 A1	05-08-2004